List of genes with >2% mutational prevalence and significant impact on OS rate in DLBCL
| Gene . | Effect on OS . | In DLBCL . | In GCB . | In ABC . | |||
|---|---|---|---|---|---|---|---|
| Mutation frequency, % . | P for OS . | Mutation frequency, % . | P for OS . | Mutation frequency, % . | P for OS . | ||
| KMT2D | Unfavorable | 23.7 | .012 | 28.5 | .005 | 17.5 | — |
| TP53 | Unfavorable | 16.3 | .0005 | 19.8 | .024 | 13.1 | .034 |
| EZH2 | Favorable | 9.3 | .007 | 17.4 | .04 | 1.9 | — |
| TET2 | Unfavorable | 5.5 | .011 | 6.4 | .011 | 4.4 | — |
| NOTCH2 | Unfavorable | 4.5 | (.061) | 2.9 | .005 | 6.9 | — |
| GNA13 | Favorable | 4.1 | .047 | 8.1 | (.09) | 0.6 | — |
| ATM | Unfavorable | 2.2 | (.085) | 1.7 | — | 2.5 | .003 |
| Gene . | Effect on OS . | In DLBCL . | In GCB . | In ABC . | |||
|---|---|---|---|---|---|---|---|
| Mutation frequency, % . | P for OS . | Mutation frequency, % . | P for OS . | Mutation frequency, % . | P for OS . | ||
| KMT2D | Unfavorable | 23.7 | .012 | 28.5 | .005 | 17.5 | — |
| TP53 | Unfavorable | 16.3 | .0005 | 19.8 | .024 | 13.1 | .034 |
| EZH2 | Favorable | 9.3 | .007 | 17.4 | .04 | 1.9 | — |
| TET2 | Unfavorable | 5.5 | .011 | 6.4 | .011 | 4.4 | — |
| NOTCH2 | Unfavorable | 4.5 | (.061) | 2.9 | .005 | 6.9 | — |
| GNA13 | Favorable | 4.1 | .047 | 8.1 | (.09) | 0.6 | — |
| ATM | Unfavorable | 2.2 | (.085) | 1.7 | — | 2.5 | .003 |
The DLBCL group had 418 patients. The GCB group, determined by gene-expression profiling, had 172 patients. The ABC group, determined by gene-expression profiling, had 160 patients. The impact on OS was based on univariate analysis for each gene. Marginal P values are in the parentheses. Dashes indicate not prognostic.